Patents by Inventor David Primer

David Primer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230128975
    Abstract: The present invention provides processes of synthesis and purification of a bromodomain inhibitor, Compound 1, which compound includes crystalline forms, amorphous forms, solvates, and hydrates thereof. Embodiments of the disclosure relate to chemical synthesis routes of Compound 1 that provide a scalable method that results in highly pure final product. A further embodiment relates to methods to isolate the most stable polymorph of Compound 1 by crystallization from formic acid and water.
    Type: Application
    Filed: December 14, 2022
    Publication date: April 27, 2023
    Applicant: Celgene Quanticel Research, Inc.
    Inventors: John Fitzgerald Traverse, Kelvin Hin-Yeong Yong, Antonio Christian Ferretti, Hekla Alite, Jonathan Moseley, Antonio Maria Ruda, David Primer, Steven Philp
  • Patent number: 11566004
    Abstract: The present invention provides processes of synthesis and purification of a bromodomain inhibitor, Compound 1, which compound includes crystalline forms, amorphous forms, solvates, and hydrates thereof. Embodiments of the disclosure relate to chemical synthesis routes of Compound 1 that provide a scalable method that results in highly pure final product. A further embodiment relates to methods to isolate the most stable polymorph of Compound 1 by crystallization from formic acid and water.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: January 31, 2023
    Assignee: CELGENE QUANTICEL RESEARCH, INC.
    Inventors: John Fitzgerald Traverse, Kelvin Hin-Yeong Yong, Antonio Christian Ferretti, Hekla Alite, Jonathan Moseley, Antonio Maria Ruda, David Primer, Steven Philp
  • Publication number: 20220064121
    Abstract: The present invention provides processes of synthesis and purification of a bromodomain inhibitor, Compound 1, which compound includes crystalline forms, amorphous forms, solvates, and hydrates thereof. Embodiments of the disclosure relate to chemical synthesis routes of Compound 1 that provide a scalable method that results in highly pure final product. A further embodiment relates to methods to isolate the most stable polymorph of Compound 1 by crystallization from formic acid and water.
    Type: Application
    Filed: July 23, 2019
    Publication date: March 3, 2022
    Applicant: Celgene Quanticel Research, Inc.
    Inventors: John Fitzgerald TRAVERSE, Kelvin Hin-Yeong Yong, Antonio Christian Ferretti, Hekla Alite, Jonathan Moseley, Antonio Maria Ruda, David Primer, Steven Philp